Company: DVAX
Filing Date: 2025-04-17
Form Type: DEFC14A
Source: 0000930413-25-001273
Chunk: 61

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-17
Form: DEFC14A
Chunk 61
---
 Dr.
Janssen was Vice President, Medical Affairs at Gilead from 2008 to 2010 where he was responsible for oversight of physician and health
care provider education focused on HIV and hepatitis B therapies. Until 2008, Dr. Janssen spent 23 years at the U.S. Centers for Disease
Control and Prevention (“CDC”), most recently as the Director of the Division of HIV/AIDS Prevention from 2000 to 2008. Under
his leadership, the CDC first explored HIV treatment as a mode of HIV prevention and launched several of the earliest Phase 3 trials of
pre-exposure prophylaxis for HIV. Dr. Janssen received a Bachelor of Arts degree with Honors in Humanities from Stanford University and
his M.D. degree from the University of Southern California. He is a neurologist with training in virology received at the University of
Pennsylvania. Dr. Janssen has been the beneficiary of numerous honors and awards during his career. He has published over 150 scientific
articles in a variety of journals and has served as a reviewer for leading scientific journals.

<div align='center'>COMPENSATION DISCUSSION AND ANALYSIS</div>

This Compensation Discussion and Analysis discusses our executive compensation
philosophy and practices and provides an overview of the Compensation Committee’s 2024 decisions for the following named executive
officers (“NEOs”):

| • | Ryan Spencer, Chief Executive Officer and Director;                                                                          |
| • | Kelly MacDonald, Senior Vice President, Chief Financial Officer;                                                             |
| • | David F. Novack, President and Chief Operating Officer;                                                                      |
| • | John Slebir, Senior Vice President, General Counsel; and                                                                     |
| • | Robert Janssen, M.D., Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs. |

Overview

Our Business

We are a commercial stage biopharmaceutical company developing and
commercializing innovative vaccines to help protect the world against infectious diseases. We are currently focused on our efforts to
drive long-term stockholder value by driving growth and maximizing the value of our lead commercial asset, HEPLISAV-B adult hepatitis
B vaccine, advancing our portfolio of differentiated vaccine candidates leveraging our core technology, CpG 1018® vaccine adjuvant,
and identifying strategic opportunities to accelerate growth.

Our first marketed product, HEPLISAV-B [Hepatitis B Vaccine (Recombinant),
Adjuvanted], is approved in the